ATE339208T1 - Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs - Google Patents
Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebsInfo
- Publication number
- ATE339208T1 ATE339208T1 AT01987667T AT01987667T ATE339208T1 AT E339208 T1 ATE339208 T1 AT E339208T1 AT 01987667 T AT01987667 T AT 01987667T AT 01987667 T AT01987667 T AT 01987667T AT E339208 T1 ATE339208 T1 AT E339208T1
- Authority
- AT
- Austria
- Prior art keywords
- progesterone receptor
- breast cancer
- receptor inhibitors
- resistant breast
- treat steroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24101000P | 2000-10-18 | 2000-10-18 | |
| DE10051609A DE10051609A1 (de) | 2000-10-18 | 2000-10-18 | Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE339208T1 true ATE339208T1 (de) | 2006-10-15 |
Family
ID=26007397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01987667T ATE339208T1 (de) | 2000-10-18 | 2001-10-17 | Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP1414465B1 (de) |
| JP (1) | JP4335525B2 (de) |
| KR (1) | KR20030044006A (de) |
| CN (1) | CN1311833C (de) |
| AT (1) | ATE339208T1 (de) |
| AU (2) | AU1595802A (de) |
| BG (1) | BG107745A (de) |
| BR (1) | BR0114677A (de) |
| CA (1) | CA2423013A1 (de) |
| CY (1) | CY1106289T1 (de) |
| CZ (1) | CZ299945B6 (de) |
| DE (1) | DE60123138T2 (de) |
| DK (1) | DK1414465T3 (de) |
| EA (1) | EA005945B1 (de) |
| EE (1) | EE200300156A (de) |
| ES (1) | ES2272561T3 (de) |
| HK (1) | HK1071697A1 (de) |
| HR (1) | HRP20030386A2 (de) |
| HU (1) | HUP0301461A3 (de) |
| IL (2) | IL154974A0 (de) |
| MX (1) | MXPA03002953A (de) |
| NO (1) | NO20031745D0 (de) |
| NZ (1) | NZ545965A (de) |
| PL (1) | PL366415A1 (de) |
| SK (1) | SK4752003A3 (de) |
| WO (1) | WO2002032429A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102006054535A1 (de) * | 2006-11-15 | 2008-05-21 | Bayer Schering Pharma Aktiengesellschaft | Progesteronrezeptorantagonisten |
| DE102009034366A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034367A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034368A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034362A1 (de) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102009034526A1 (de) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten |
| DE102009034525A1 (de) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten |
| DE102010007719A1 (de) * | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
| DE102010007722A1 (de) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesteronrezeptorantagonisten |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0466315A3 (en) * | 1990-05-30 | 1992-07-01 | Larrian Gillespie | Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation |
| US5238950A (en) * | 1991-12-17 | 1993-08-24 | Schering Corporation | Inhibitors of platelet-derived growth factor |
| DE19706061A1 (de) * | 1997-02-07 | 1998-08-13 | Schering Ag | Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette |
| PE20000129A1 (es) * | 1997-12-23 | 2000-03-11 | Schering Ag | 11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa |
| FR2789393B1 (fr) * | 1999-02-05 | 2001-10-12 | Centre Nat Rech Scient | Lactol steroidique |
-
2001
- 2001-10-17 WO PCT/EP2001/012004 patent/WO2002032429A2/en active IP Right Grant
- 2001-10-17 PL PL01366415A patent/PL366415A1/xx not_active Application Discontinuation
- 2001-10-17 CA CA002423013A patent/CA2423013A1/en not_active Abandoned
- 2001-10-17 KR KR10-2003-7005358A patent/KR20030044006A/ko not_active Application Discontinuation
- 2001-10-17 BR BR0114677-7A patent/BR0114677A/pt not_active Application Discontinuation
- 2001-10-17 AU AU1595802A patent/AU1595802A/xx active Pending
- 2001-10-17 DK DK01987667T patent/DK1414465T3/da active
- 2001-10-17 SK SK475-2003A patent/SK4752003A3/sk unknown
- 2001-10-17 AT AT01987667T patent/ATE339208T1/de not_active IP Right Cessation
- 2001-10-17 EP EP01987667A patent/EP1414465B1/de not_active Expired - Lifetime
- 2001-10-17 ES ES01987667T patent/ES2272561T3/es not_active Expired - Lifetime
- 2001-10-17 EA EA200300468A patent/EA005945B1/ru not_active IP Right Cessation
- 2001-10-17 DE DE60123138T patent/DE60123138T2/de not_active Expired - Fee Related
- 2001-10-17 JP JP2002535667A patent/JP4335525B2/ja not_active Expired - Fee Related
- 2001-10-17 CN CNB018173853A patent/CN1311833C/zh not_active Expired - Fee Related
- 2001-10-17 EE EEP200300156A patent/EE200300156A/xx unknown
- 2001-10-17 CZ CZ20031071A patent/CZ299945B6/cs not_active IP Right Cessation
- 2001-10-17 MX MXPA03002953A patent/MXPA03002953A/es active IP Right Grant
- 2001-10-17 AU AU2002215958A patent/AU2002215958B2/en not_active Ceased
- 2001-10-17 IL IL15497401A patent/IL154974A0/xx active IP Right Grant
- 2001-10-17 HU HU0301461A patent/HUP0301461A3/hu unknown
- 2001-10-17 NZ NZ545965A patent/NZ545965A/en unknown
-
2003
- 2003-03-18 IL IL154974A patent/IL154974A/en not_active IP Right Cessation
- 2003-04-15 NO NO20031745A patent/NO20031745D0/no not_active Application Discontinuation
- 2003-04-18 BG BG107745A patent/BG107745A/bg unknown
- 2003-05-14 HR HR20030386A patent/HRP20030386A2/hr not_active Application Discontinuation
-
2005
- 2005-05-31 HK HK05104537A patent/HK1071697A1/xx not_active IP Right Cessation
-
2006
- 2006-12-12 CY CY20061101786T patent/CY1106289T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE323474T1 (de) | Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs | |
| ATE339957T1 (de) | Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs | |
| DE60040981D1 (de) | BEHANDLUNG MIT ANTI-ErbB2 ANTIKÖRPERN | |
| ATE372341T1 (de) | Inhibitoren von mitotischem kinesin | |
| DE69830072D1 (de) | Radioaktive zusammensetzungen zur behandlung von prostatatumoren | |
| EA199800391A1 (ru) | Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору | |
| ATE295735T1 (de) | Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs | |
| CY1106289T1 (el) | Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη | |
| ATE222119T1 (de) | Verwendung von erythropoietin zur behandlung von multiple myelom | |
| ATE410235T1 (de) | Behandlung von ballastwasser | |
| DE69912743D1 (de) | Behandlung von follikulären lymphomen unter verwendung von inhibitoren des lymphotoxin (lt)-aktivierungsweges | |
| YU30003A (sh) | Inhibicija zavisnosti faktora rasta na ćelije tumora | |
| DE60137721D1 (de) | Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs | |
| ATE333869T1 (de) | Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen | |
| ATE320255T1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
| DE69935156D1 (de) | hCG THERAPIE ZUR BEHANDLUNG VON METASTATISCHEM BRUSTKREBS | |
| DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen | |
| ATE298244T1 (de) | Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen | |
| DE60143023D1 (de) | Tumorhemmende nitroacridin-zusammensetzungen | |
| ATE291434T1 (de) | Verwendung von angiotensin zur behandlung von krebsmetastasierung | |
| ATE521351T1 (de) | Verwendung von 7-t-butoxyiminomethylcamptothecin zur behandlung von gebärmuttertumoren | |
| DE10193322D2 (de) | Verwendung von Protonenpumpen-Hemmern zur Behandlung von Erkrankungen des Bewegungsapparates | |
| ATE349215T1 (de) | Die verwendung von estrogen-verbindungen zur behandlung von osteoporose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1414465 Country of ref document: EP |
|
| EEFA | Change of the company name | ||
| REN | Ceased due to non-payment of the annual fee |